Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Discover our news

Upcoming events

Discover all events

Press contacts

Celyad

Nicolas Van Hoecke
Director, Investor Relations & Communications

+32 (0)10 39 41 84

Stern Investor Relations (US)

Will O’Connor, Michael Schaffzin

+1 212 362 1200

Consilium Strategic Communications (UK)

Chris Welsh, Chris Gardner

+44 20 3709 5700

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91